Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Total Liabilities (2022 - 2025)

Ascentage Pharma Group International posted quarterly Total Liabilities of $370.7 million for Q4 2025, up 13.62% year-on-year from $326.3 million in Q4 2024, and up 13.62% on a QoQ basis from $326.3 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 4 years of Total Liabilities data on file, last reported at $370.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 13.62% year-over-year to $370.7 million; the trailing twelve-month figure through Dec 2025 stood at $370.7 million (up 13.62% YoY), and the FY2025 full-year result was $376.0 million, up 17.1% from the prior year.
  • Total Liabilities for Q4 2025 stood at $370.7 million, up from $326.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $370.7 million in Q4 2025 and bottomed at -$57.5 million in Q4 2022.
  • The 4-year median for Total Liabilities is $331.9 million (2023), against an average of $244.2 million.
  • The widest annual swing landed in 2023, when Total Liabilities jumped 687.31%; it then dropped 3.32% in 2024.
  • A 4-year view of Total Liabilities shows it stood at -$57.5 million in 2022, then surged by 687.31% to $337.5 million in 2023, then slipped by 3.32% to $326.3 million in 2024, then grew by 13.62% to $370.7 million in 2025.
  • The last three Total Liabilities figures came in at $370.7 million (Q4 2025), $326.3 million (Q4 2024), and $337.5 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 16.35 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 1.74 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 731.60 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 177.22 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 19.51 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 7.12 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 9.45 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - 10.44 Mn
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 4.05 Bn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 370.72 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 370.72 Mn
Dec 31, 2024 326.27 Mn
Dec 31, 2023 337.46 Mn
Dec 31, 2022 -57.46 Mn